+ Follow AMAL KELSHIKAR Tag
AMAL KELSHIKAR
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 760500
[Title] => New indication timely gift for type 2 diabetes patients
[Summary] => With the many sumptuous feasts and gastronomic temptations it brings, the Christmas season is often a dilemma for patients with diabetes trying to keep their blood sugar level in check.
[DatePublished] => 2011-12-22 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 719783
[Title] => Arthritis drug launched
[Summary] => Pain relief for patients with chronic arthritis has always been problematic because non-steroidal anti-inflammatory drugs (NSAIDs), one of the most widely prescribed agents for these conditions, cause gastrointestinal side effects such as stomach ulcers.
[DatePublished] => 2011-08-25 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 638698
[Title] => Gird up against GERD
[Summary] => You can be a candidate for GERD this holiday season. GERD is the acronym for gastro-esophageal reflux disease, a condition where gastric juices containing acid travel back from the stomach to the esophagus.
[DatePublished] => 2010-12-14 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] => 1422176
[AuthorName] => Joy Angelica Subido
[SectionName] => Health And Family
[SectionUrl] => health-and-family
[URL] =>
)
[3] => Array
(
[ArticleID] => 630709
[Title] => Better GERD diagnosis, treatment pushed
[Summary] => Research-based pharmaceutical company AstraZeneca is working with specialists to “localize” a patient questionnaire that can help primary care physicians better diagnose gastroesophageal reflux disease (GERD), a common digestive disorder that is often undiagnosed, untreated and improperly managed.
[DatePublished] => 2010-11-18 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[4] => Array
(
[ArticleID] => 626492
[Title] => AstraZeneca's gefitinib gets FDA approval
[Summary] => Research-based pharmaceutical company AstraZeneca’s targeted cancer therapy gefitinib has received approval from the Philippine Food and Drug Administration (FDA) as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).
[DatePublished] => 2010-11-04 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[5] => Array
(
[ArticleID] => 603626
[Title] => Partnership forged to curb diabetes cases
[Summary] => Alarmed at the growing prevalence of diabetes in the country, societies dealing with the epidemic of type 2 diabetes, including the American Association of Clinical Endocrinologists (AACE) Philippine Chapter and Diabetes Philippines (DP), have partnered with research-based biopharmaceutical company AstraZeneca to increase public awareness on diabetes prevention and management.
[DatePublished] => 2010-08-19 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[6] => Array
(
[ArticleID] => 584585
[Title] => AstraZeneca's anti-cholesterol drug shows benefits in cardiovascular disease management
[Summary] => Two recent studies have shown that the AstraZeneca anti-cholesterol drug rosuvastatin demonstrated ability to reduce the risk of cardiovascular disease and is better than simvastatin and atorvastatin in the overall management of hypercholesterolemia.
[DatePublished] => 2010-06-17 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[7] => Array
(
[ArticleID] => 530595
[Title] => AstraZeneca 'personalized healthcare' customizes treatments for patients
[Summary] => Guided by a better understanding of diseases and the differences among patients, one of the world’s leading pharmaceutical companies, AstraZeneca, is adopting a “personalized” approach to healthcare, particularly in developing targeted cancer treatments.
[DatePublished] => 2009-12-10 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[8] => Array
(
[ArticleID] => 14809
[Title] => Novartis gears up for Biocamp 2007
[Summary] =>
[DatePublished] => 2007-08-23 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
December 22, 2011 - 12:00am
August 25, 2011 - 12:00am
November 18, 2010 - 12:00am
November 4, 2010 - 12:00am
August 19, 2010 - 12:00am
December 10, 2009 - 12:00am
August 23, 2007 - 12:00am
